表紙
市場調查報告書

焦點市場分析:前列腺肥大症 (BPH)

Market Spotlight: Benign Prostatic Hyperplasia (BPH)

出版商 Datamonitor Healthcare 商品編碼 603948
出版日期 內容資訊 英文 35 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
焦點市場分析:前列腺肥大症 (BPH) Market Spotlight: Benign Prostatic Hyperplasia (BPH)
出版日期: 2019年12月31日內容資訊: 英文 35 Pages
簡介

全球40歲以上的男性的前列腺肥大症的患病人數預測將從2017年的2億9,320萬人,增加到2026年3億5,870萬人。2017年,亞洲患病人數最多(1.801億),大洋洲最低(190萬)。

本報告提供全球前列腺肥大症 (BPH)的治療藥的市場調查,彙整疾病的背景·概要,發病數的十年預測,主要的治療方法,主要的開發平台藥物概要,主要的已上市藥物趨勢,授權·資產收購等企業間的主要交易趨勢,專利資訊,臨床試驗狀況等資料。

概要

要點

疾病的背景

治療

  • 後續觀察
  • 藥理的治療
  • 外科的治療

流行病學

已上市藥物

開發平台藥物

近幾年趨勢·分析師的見解

成功概率

授權·資產收購等的交易

母專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:不同階段

文獻

  • 處方資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0184659

This Market Spotlight report covers the Benign Prostatic Hyperplasia market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 293.2 million prevalent cases of benign prostatic hyperplasia (BPH) among males aged 40 years and older worldwide, and forecasts that number to increase to 358.7 million prevalent cases by 2026. Asia is estimated to have had the largest number of prevalent cases in 2017, and Oceania is estimated to have had the smallest number (180.1 million and 1.9 million cases, respectively).

Approved drugs in the BPH space target phosphodiesterase 5, steroid 5a-reductase, alpha 1 adrenergic receptor, and muscarinic acetylcholine receptor. All marketed drugs for BPH are administered via the oral route.

The largest proportion of industry-sponsored drugs in active clinical development for BPH are in Phase II, with two drugs in Phase III.

Therapies in development for BPH focus on a wide variety of targets. These therapies are administered via the rectal, percutaneous catheter/injection, intratumoral, intravenous, and oral routes.

The overall likelihood of approval of a Phase I urology asset is 12.4%, and the average probability a drug advances from Phase III is 76.2%. Drugs, on average, take 8.5 years from Phase I to approval in the overall urology space.

There have been only four licensing and asset acquisition deals involving BPH drugs during 2014-19. The $8.2m agreement between Aceto and Par Pharmaceutical signed in 2014, under which Aceto's subsidiary, Rising Pharmaceuticals, purchased three ANDAs from Par Pharmaceutical through the acquisition of doxercalciferol, paricalcitol, and dutasteride capsules, was the only deal with a disclosed value.

The distribution of clinical trials across Phase I-IV indicates that just over half of trials for BPH have been in the early and midphases of development, with 53% of trials in Phase I-II, and 47% in Phase III-IV.

The US has a substantial lead in the number of BPH clinical trials globally. Germany leads the major EU markets, while South Korea has the top spot in Asia.

Clinical trial activity in the BPH space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for BPH, with 65 trials.

GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for BPH, followed by Astellas and Sanofi.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Watchful waiting
  • Pharmacological treatment
  • Surgical treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Multiple Drugs for BPH (June 25, 2019)
  • OPK-88004 for BPH (January 31, 2019)
  • Multiple Devices for BPH (November 20, 2018)

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of BPH, 2017-26
  • Figure 2: Overview of pipeline drugs for BPH in the US
  • Figure 3: Pipeline drugs for BPH, by company
  • Figure 4: Pipeline drugs for BPH, by drug type
  • Figure 5: Pipeline drugs for BPH, by classification
  • Figure 6: Probability of success in the BPH pipeline
  • Figure 7: Licensing and asset acquisition deals in BPH, 2014-19
  • Figure 8: Parent patents in BPH
  • Figure 9: Clinical trials in BPH
  • Figure 10: Top 10 drugs for clinical trials in BPH
  • Figure 11: Top 10 companies for clinical trials in BPH
  • Figure 12: Trial locations in BPH
  • Figure 13: BPH trials status
  • Figure 14: BPH trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of BPH, 2017-26
  • Table 2: Prevalence proportions of BPH, by age, 2017-26
  • Table 3: Marketed drugs for BPH
  • Table 4: Pipeline drugs for BPH in the US
  • Table 5: Multiple Drugs for BPH (June 25, 2019)
  • Table 6: OPK-88004 for BPH (January 31, 2019)
  • Table 7: Multiple Devices for BPH (November 20, 2018)
  • Table 8: Historical global sales, by drug ($m), 2014-18
  • Table 9: Forecasted global sales, by drug ($m), 2019-23
Back to Top